Share on StockTwits

Equities researchers at Canaccord Genuity began coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a research report issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) opened at 23.99 on Thursday. Aerie Pharmaceuticals has a 52 week low of $10.25 and a 52 week high of $29.71. The stock’s 50-day moving average is $18.44 and its 200-day moving average is $18.65. The company’s market cap is $562.3 million. Aerie Pharmaceuticals also was the recipient of a significant decrease in short interest during the month of June. As of June 13th, there was short interest totalling 432,812 shares, a decrease of 25.9% from the May 30th total of 584,343 shares. Based on an average daily trading volume, of 178,623 shares, the days-to-cover ratio is presently 2.4 days. Approximately 5.0% of the shares of the company are short sold.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings data on Monday, May 12th. The company reported ($0.28) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.35) by $0.07. Analysts expect that Aerie Pharmaceuticals will post $-1.49 EPS for the current fiscal year.

AERI has been the subject of a number of other recent research reports. Analysts at RBC Capital raised their price target on shares of Aerie Pharmaceuticals from $27.00 to $36.00 in a research note on Thursday, June 26th. They now have an “outperform” rating on the stock. Separately, analysts at Needham & Company LLC raised their price target on shares of Aerie Pharmaceuticals from $26.00 to $37.00 in a research note on Thursday, June 26th. They now have a “buy” rating on the stock.

Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.